Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

 


The Offering

Common stock offered by us

                      shares

Common stock to be outstanding after this offering

 

                    shares

Underwriters' option

 

The underwriters have an option for a period of 30 days to purchase up to                        additional shares of our common stock.

Use of proceeds

 

We intend to use the net proceeds of this offering, together with our existing cash reserves to advance our development of VTP-43742, VTP-38443 and VTP-38543, to fund our continued discovery efforts to identify additional drug candidates for new therapeutic molecular targets, including our immuno-oncology program, and for working capital, debt maintenance and general corporate purposes. See "Use of Proceeds" in this prospectus for a more complete description of the intended use of proceeds from this offering.

Risk factors

 

You should read the "Risk Factors" section of this prospectus beginning on page 11 for a discussion of factors to consider carefully before deciding to invest in shares of our common stock.

Proposed NASDAQ Global Market trading symbol

 

VTAE

        The shares of common stock to be outstanding after this offering is based on shares of common stock outstanding as of June 30, 2014, after giving effect to the conversion of all of our outstanding shares of preferred stock into 218,309,741 shares of our common stock and excludes:

    1,045,834 shares issuable upon the exercise of warrants outstanding as of June 30, 2014, at a weighted-average exercise price of $1.19 per share;
    35,252,515 shares of common stock issuable upon the exercise of options outstanding as of June 30, 2014, with a weighted-average exercise price of $0.19 per share;
    9,000,000 shares of common stock subject to restricted stock units, or RSUs, outstanding as of June 30, 2014;
    1,070,687 shares of common stock reserved for future grants under our 2013 Stock Plan, 2004 Stock Plan and 2001 Stock Plan as of June 30, 2014;
    shares of common stock reserved for future grants under our 2014 Equity Incentive Plan, which became effective in                        2014 (subject to automatic annual adjustment in accordance with the terms of the plan), but with respect to which no awards will be granted prior to the completion of the offering; and
    shares reserved for future issuance under our 2014 Employee Stock Purchase Plan, which became effective in                        2014 but with respect to which no shares will be purchased prior to the effective date of the registration statement of which this prospectus is a part, subject to automatic annual adjustment in accordance with the terms of the plan.

        Unless otherwise noted, the information in this prospectus assumes:

    that our restated certificate of incorporation, which we will file in connection with the completion of this offering, is in effect;

 

7